TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing–remitting multiple sclerosis
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-3974-7
Abstract: PurposeExpression of the translocator protein (TSPO) is upregulated in activated macrophages/microglia and is considered to be a marker of neuroinflammation. We investigated the novel TSPO ligand [18F]GE-180 in patients with relapsing–remitting multiple sclerosis (RRMS) to… read more here.
Keywords: tspo; pet; relapsing remitting; 18f 180 ... See more keywords
P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Neurophysiology"
DOI: 10.1016/j.clinph.2017.06.080
Abstract: Background Ocrelizumab (OCR) is a humanised monoclonal antibody that selectively targets CD20+B cells. The pathogenesis of multiple sclerosis (MS), including neurodegeneration, is thought to be influenced by B cells. Volumetric magnetic resonance imaging (MRI) measurements… read more here.
Keywords: week; volume; matter volume; patients relapsing ... See more keywords
The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2019.1565818
Abstract: Abstract Background: There is limited evidence on the effectiveness and healthcare costs of switching to fingolimod versus another first line injectable therapy (FLIT) in patients with relapsing multiple sclerosis (RMS) who have already been treated… read more here.
Keywords: switching fingolimod; first line; fingolimod versus; cohort ... See more keywords
Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Neurology"
DOI: 10.1111/ene.15579
Abstract: Measures of atrophy in the whole brain can be used to reliably assess treatment effect in clinical trials of patients with multiple sclerosis (MS). Trials assessing the effect of treatment on grey matter (GM) and… read more here.
Keywords: matter; matter atrophy; grey matter; treatment ... See more keywords
Clinical features of Chinese patients with relapsing polychondritis
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Ophthalmology"
DOI: 10.1136/bjophthalmol-2018-312660
Abstract: Purpose To characterise the ocular and extraocular findings in patients with relapsing polychondritis (RP) patients. Design Retrospective, longitudinal study. Methods A total number of 16 patients with ocular RP, seen in our tertiary uveitis referral… read more here.
Keywords: female patients; clinical features; chinese patients; patients relapsing ... See more keywords
Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0185766
Abstract: Background Treatment satisfaction in patients with relapsing-remitting multiple sclerosis (RRMS) may impact adherence and thus clinical outcomes. The objective of this study was to measure the satisfaction of patients with RRMS with injectable disease-modifying therapies… read more here.
Keywords: satisfaction; treatment; disease; study ... See more keywords